Tumor-infiltrating lymphocyte (TIL) cell therapy is a promising option for patients with advanced melanoma, but logistical and referral challenges can be a barrier to care. In this episode, CANCER BUZZ speaks with Lilit Karapetyan, MD, MS, FACP, medical oncologist at Moffit Cancer Center and Research Institute, an authorized treatment center (ATC) for TIL cell therapy, and Raju Vaddepally, MD, hematologist-oncologist at Florida Cancer Specialists, a non-ATC, about the referral process. Both guests discuss the relationship between their cancer programs, offering actionable tips on how to streamline the identification and referral of melanoma patients for TIL therapy across institutions.

Guests:

Lilit Karapetyan, MD, MS, FACP Medical Oncologist Moffitt Cancer Center and Research Institute Tampa, FL

Raju Vaddepally, MD Hematologist-Oncologist Florida Cancer Specialists Naples, FL

"It is extremely important that providers think about this earlier, because the huge issue that we have with TIL therapy is that we get a lot of patients referred but unfortunately, they are no longer fit to proceed with the therapy." - Lilit Karapetyan, MD, MS, FACP

"Cancer care can be so fragmented and always requires multidisciplinary input, whether it be within the town or going to an academic center, so we do have a specialized department in which they handle all these referrals." - Raju Vaddepally, MD

Resources

• ACCC TIL Therapy Resources

• ACCCBuzz Blog: Streamlining TIL Cell Therapy: ACCC Resources to Improve Referral Pathways and Academic–Community Coordination

• CANCER BUZZ: Developments in TIL Cell Therapy